The application of gene therapy in China

IDrugs

Volumn 11, Issue 5, 2008, Pages 346-350

  Peng, Z ^a   Yu, Q ^a   Bao, L ^a  

^a Shenzhen SiBiono GeneTech Co Ltd   (China)

Author keywords

China; Gendicine; Gene therapy; Guideline

Indexed keywords

ADENOVIRUS VECTOR; GENDICINE; HERPESVIRUS VECTOR; PLASMID VECTOR; RETROVIRUS VECTOR;

AUTOIMMUNE DISEASE; BIOTECHNOLOGY; CARDIOVASCULAR DISEASE; CHINA; CLINICAL PROTOCOL; COMMERCIAL PHENOMENA; DRUG EFFICACY; DRUG MANUFACTURE; GENE THERAPY; GENETIC DISORDER; GENETIC TRANSDUCTION; GOVERNMENT REGULATION; INFECTION; MEDICAL RESEARCH; NEOPLASM; PATENT; PRACTICE GUIDELINE; REGISTRATION; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; CHINA; DIFFUSION OF INNOVATION; GENE THERAPY; GENETIC VECTORS; GOVERNMENT REGULATION; HEALTH POLICY; HUMANS; LEGISLATION, DRUG; PRACTICE GUIDELINES AS TOPIC; RECOMBINANT PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 43549090178     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Gene therapy clinical trials worldwide: John Wiley & Sons Inc, Hoboken, NJ, USA (2008). www.wiley.co.uk/genetherapy/clinical
2. Peng ZH: Current status of Gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers. Human Gene Ther (2005) 16(9):1014-1027.
3. Deng HX, Tian L, Wei YQ: Current status, problems and prospects in gene therapy. Chinese Bulletin of Life Sciences (2005) 17(3):196-199.
4. State Food and Drug Administration of China: Points to consider for human gene therapy and product quality control. BioPharm International (2004) 17(5):73-76.
5. Yin HZ: Regulations and procedures for new drug evaluation and approval in China. Human Gene Ther (2006) 17(10):970-974.